Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma

T. Flaherty, Keith; Robert, Caroline; Hersey, Peter; Nathan, Paul; Garbe, Claus; Milhem, Mohammed; Demidov, Lev; C. Hassel, Jessica; Rutkowski, Piotr; Mohr, Peter; Dummer, Reinhard; Trefzer, Uwe; Larkin, James; Utikal, Jochen; Dréno, Brigitte; Nyakas, Marta; R. Middleton, Mark; C. Becker, Jürgen; Casey, Michelle; Sherman, Laurie; Wu, Frank; Ouellet, Danièle; Martin, Anne‐Marie; Klaus Patel, Kiran; Schadendorf, Dirk

doi:10.1056/nejmoa1203421

Public

Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma

Published in New England Journal of Medicine • Jun 14, 2012

Authors:

Keith T. Flaherty

Caroline Robert

Peter Hersey

Abstract

BACKGROUND: Activating mutations in serine-threonine protein kinase B-RAF (BRAF) are found in 50% of patients with advanced melanoma. Selective BRAF-inhibitor therapy improves survival, as compared with chemotherapy, but responses are often short-lived. In previous trials, MEK inhibition appeared to...

Subject

Trametinib

Medicine

Dabrafenib

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!